← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 67.3% to $2.0M, while Net income decreased 91.1% to ($162.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $2.0MWatch
- Profitability — Net income ($162.3M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — Distress-safe · no manipulation flag · earnings quality not computedNote
- Insiders — 0 buys; 12 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Dianthus Therapeutics, Inc. /DE/: Our Pipeline Our Pipeline-in-a-Product Potential for Claseprubart, a Next-Generation Complement Therapeutic Our most advanced product candidate, claseprubart, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s.
Where the revenue comes from
Fiscal 2025, as Dianthus Therapeutics, Inc. /DE/ reports it. History and quarterly detail are in the app.
Leadership changes
From Dianthus Therapeutics, Inc. /DE/'s own filings, the day they're filed.
- Simon Read · director · appointmenteff. 2025-05-22
- Leon O. Moulder Jr · departureeff. 2025-05-22
- Sujay Kango · director · appointmenteff. 2025-03-04
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-22
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Dianthus Therapeutics, Inc. /DE/, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.